United Health Products (OTCMKTS:UEEC) vs. Insulet (NASDAQ:PODD) Head-To-Head Survey

United Health Products (OTCMKTS:UEEC) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for United Health Products and Insulet, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Health Products	0	0	0	0	0.00
Insulet	1	3	20	0	2.79

Insulet has a consensus price target of $354.57, suggesting a potential upside of 42.90%. Given Insulet’s stronger consensus rating and higher possible upside, analysts clearly believe Insulet is more favorable than United Health Products.

Earnings and Valuation

This table compares United Health Products and Insulet”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Health Products	N/A	N/A	-$2.00 million	($0.02)	-2.87
Insulet	$2.71 billion	6.45	$247.10 million	$3.50	70.89

Insulet has higher revenue and earnings than United Health Products. United Health Products is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

United Health Products has a beta of -0.86, indicating that its share price is 186% less volatile than the S&P 500. Comparatively, Insulet has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Institutional & Insider Ownership

0.1% of United Health Products shares are owned by institutional investors. 1.5% of United Health Products shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares United Health Products and Insulet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
United Health Products	N/A	N/A	-2,141.74%
Insulet	9.12%	24.90%	10.73%

Summary

Insulet beats United Health Products on 11 of the 13 factors compared between the two stocks.

About United Health Products

United Health Products, Inc. develops, manufactures, and markets hemostatic gauze products for the healthcare and wound care sectors in the United States. The company offers HemoStyp hemostatic gauze products to absorb exudate/drainage from superficial wounds, as well as helps in controlling bleeding. It serves hospitals and surgery centers, clinics and physicians, military medical care providers, hemodialysis centers, nursing homes and assisted living, and veterinary hospitals; and EMS, fire departments, and other first responders, as well as dental, oral, and maxillofacial surgery offices. The company was formerly known as United EcoEnergy Corp. and changed its name to United Health Products, Inc. in September 2010. United Health Products, Inc. was incorporated in 1997 and is headquartered in Mount Laurel, New Jersey.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.